Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion

• Prif Awduron: Yoshiyuki Arata (Awdur), Shigeki Motoyama (Awdur), Mariko Yano (Awdur), Tatsuya Ikuno (Awdur), Shunsuke Ito (Awdur), Tomochika Matsushita (Awdur), Akira Takeiri (Awdur), Yukari Nishito (Awdur), Nami Yabuki (Awdur), Hideaki Mizuno (Awdur), Zenjiro Sampei (Awdur), Masayuki Mishima (Awdur), Masaki Honda (Awdur), Jumpei Kiyokawa (Awdur), Hiromi Suzuki (Awdur), Shuichi Chiba (Awdur), Mitsuyasu Tabo (Awdur), Chiyomi Kubo (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

ABSTRACTTherapeutic antibodies sometimes elicit anti-drug antibodies (ADAs) that can affect efficacy and safety. Engineered antibodies that contain artificial amino acid sequences are potentially highly immunogenic, but this is currently difficult to predict. Therefore, it is important to efficientl...